
Synlogic reports Q3 results, including underwritten public offering of $21.0M and $2.5M milestone payment from Roche
Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases, today reported financial results for the third quarter ended September 30, 2023, and provided […]